Union 2025

TB VACCINES @ UNION WORLD CONFERENCE ON LUNG HEALTH

This page provides a list of sessions, presentations, and posters at the Union Conference related to TB vaccine R&D, as well as sessions that may be of interest to the TB vaccine R&D community. Registration is required for all Union Conference sessions.

All times are Central European Time (click here to convert to your local time zone)

Click here for the full program and more information about the Union World Conference on Lung Health

Monday, 17 November

13:30 - 19:00
Innovate, Integrate, Impact. A symposium on New Tools to End TB
Panum Building, University of Copenhagen
The event will be live-streamed

Organized by the Stop TB Partnership, FIND, New Diagnostics Working Group, Working Group on New TB Vaccines, Working Group on New TB Drugs, and NIVI.

Free of charge. Pre-registration required.

Tuesday, 18 November

11:30 - 13:00
Special Session: From exclusion to inclusion: Building consensus on integrating pregnant and lactating women in TB drug and vaccine research

13:15 - 14:15
E-posters: Childhood TB: Diagnosis and case-finding
Assessment of paediatric tuberculosis case prevalence among Bacillus Calmette-Guerin vaccinated paediatric age group in Delta State Nigeria. Eziashi Emmanuel Ajumuka (Nigeria)

Wednesday, 19 November

9:15 - 10:45
Special Session: A 360° dialogue on ending TB: Ambition, evidence, and equity
10:00 - 10:10 - The role of vaccines. Keren Middelkoop (South Africa)

TBScience Moderated E-posters II
09:15 - 09:20 - Design optimization for a global phase 3 trial of the M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine. Amy Cinar (USA)

09:20 - 09:25 - What is the potential impact of vaccinating younger (9 - 14 year old) adolescents with new TB vaccines? Rebecca A. Clark (United Kingdom)

09:35 - 09:40 - Improving collaboration through access: A scoping review of TB clinical trial repositories. Mairi McClean (German)

09:40 - 09:45 - Phosphatidylcholine alterations correlate with natural and M. tuberculosis-specific antibody responses in a primate model. Sofia Santiago Torres (USA)

15:55 - 17:25
Symposium: How can asymptomatic TB help the development and global impact of new TB vaccines?

Thursday, 20 November

8:00 - 9:00
TBScience Session: AI Design of products: Drugs, vaccines, diagnostics
8:18 - 8:33 - Vaccines. Isabelle Bekeredjian Ding (Germany)

13:10 - 14:10
E-posters: Uniting forces: Collaborative strategies and policies driving TB progress
13:50 - 13:55 - Stakeholder perspectives on new tuberculosis vaccine introduction in Indonesia: Concerns and priorities. Ahmad Fuady (Indonesia)

TBScience Moderated E-posters VI
13:20 -13:25 - Novel nanoparticle respiratory tract mucosal tuberculosis vaccine. Frederick Quinn (USA)

15:55 - 17:25
Symposium: Implementation research to prepare for the introduction of new TB vaccines for adults and adolescents

Special Session: Sustaining momentum: Collective strategies for advancing TB innovation

Oral Abstract Session: Prevention, diagnosis, and treatment for people living with HIV
15:58 - 16:05 - Assessing TB vaccine confidence in South African adults with HIV. Alexa Giovanatti (United States)

Friday, 21 November

8:00 - 9:00
TB Science Session: TB vaccines and immune correlates of risk and protection

9:05 - 9:50
TB Science Session: Mixed oral abstract presentations IV
Immunogenicity and efficacy of replication-limited or irradiation-inactivated BCG delivered intravenously to rhesus macaques. Patricia Darrah (United States)

Immunogenicity of the novel TB vaccine H107e/CAF®10b in BCG exposed, Mtb-uninfected adults in South Africa. Cecilia Lindestam Arlehamn (Denmark)

9:15 - 10:45
Oral Abstract Session: Advancing TB care: Innovations in drugs, vaccines, diagnostics and treatment
9:39 - 9:46 - Safety of the novel TB vaccine H107e/CAF®10b in BCG exposed, M.tuberculosis-uninfected adults in Gauteng, South Africa: First in human trial. Vaneshree Govender (South Africa)

9:46 - 9:53 - Enhancing the acceptability of a phase three TB vaccine trial in the Matlosana sub-district of South Africa: Using the Social Marketing Model. Blossom Napoleon (South Africa)

9:53 - 10:00 - Imprecision in TB infection outcomes: Implications for non-inferiority vaccine trials. Daniel Grint (London, United Kingdom)

10:00 - 11:00
TBScience Session: What should we prioritise for prevention of TB? Vaccines vs. antimycobacterials vs. nutritional intervention? - Panel discussion

12:15 - 13:45
Satellite Session: Accelerating Country Readiness for Introduction of New TB Vaccines for Adolescents and Adults: Perspectives from High-Burden TB Countries

13:10 - 14:10
E-posters: Innovations in TB Modelling for vaccination, diagnosis, and treatment
13:15 - 13:20 - Targeted TB vaccination strategies in India: Impact of risk-based vs. geographic approaches using mathematical modelling. Ruchita Jalal (India)

13:25 - 13:30 - The delivery of new tuberculosis vaccines to people living with HIV - When to vaccinate? Tom Sumner (United Kingdom)

14:10 - 15:40
Symposium: It takes a village: Advancing late-stage TB vaccine trials in adults and adolescents through global collaboration

Oral Abstract Session: Informing evidence-based TB policies
14:29 - 14:36 - New drugs, diagnostics and vaccines in India: Their potential impact on TB burden, and priorities for their development. Sandip Mandal (India)

Short Oral Abstract Session: Geospatial analytics and mapping for TB prevention, detection and care
14:47 - 14:55 - Mapping BCG vaccination coverage in Africa, 1990-2022: A novel spatiotemporal modelling study. Alemneh Liyew (Australia)

TBScience Moderated E-Posters X
14:25 - 14:30 - Population impact of new TB vaccines may depend on efficacy against infectious asymptomatic TB: A modelling study. Rebecca A. Clark (United Kingdom)

14:50 - 14:55 - Mycobacterium tuberculosis complex lineage 1: A frequent but neglected cause of tuberculosis with implications for vaccine design. Venus Marie Rojas (Switzerland)

TBScience Unmoderated E-Posters

New tuberculosis diagnostic technologies enable decentralized participant-driven active case detection vaccine efficacy trials with asymptomatic TB endpoints Morten Ruhwald (Denmark)

Protective efficacy and immunogenicity of Hsp16.3ΔC4 subunit vaccine against Mycobacterium tuberculosis infection S. Raghav (India)

Unveiling the binding preferences of novel HLA-E-restricted Mycobacterium tuberculosis peptides: A step towards correlating binding with Immunogenicity in TB vaccine development Nkanyezi Masonda (South Africa)

Is there other TB vaccine-related content at the Union Conference? Contact us to let us know so we can add it to this list!